Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome

Clinical Chemistry

Volumn 54, Issue 12, 2008, Pages 2007-2017

  Clark, Jarrod P ^a   Munson, Kristofer W ^a,c   Gu, Jessie W ^b   Lamparska Kupsik, Katarzyna ^a   Chan, Kevin G ^c   Yoshida, Jeffrey S ^c   Kawachi, Mark H ^c   Crocitto, Laura E ^c   Wilson, Timothy G ^c   Feng, Ziding ^b   Smith, Steven S ^a,c  

^a City of Hope   (United States)

^b USA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; APC GENE; ARTICLE; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; DNA METHYLATION; GENE EXPRESSION; GENE FUSION; GLEASON SCORE; GSTP1 GENE; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; OUTCOME ASSESSMENT; PCA3 GENE; PLASMID; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE ASSAY; RARB GENE; RASSF1 GENE; TMPRSS2 ERG FUSION GENE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; ANTIGENS, NEOPLASM; BIOPSY; DNA METHYLATION; GENETIC VARIATION; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 57149093078     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.108845     Document Type: Article

References (19)

1. O'Dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000;55:553-9.
2. National Cancer Institute. Prostate cancer. http://www.cancer.gov/ cancertopics/types/prostate (Accessed November 2008).
3. Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007;69:714-20.
4. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005;23:6569-75.
5. Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H. Molecular markers for prostate cancer. Cancer Lett 2007;249:5-13.
6. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-5.
7. van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 2007;67:881-7.
8. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95.
9. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-41.
10. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (Wash DC) 2005;310:644-8.
11. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-51.
12. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-63.
13. Stark GR, Debatisse M, Giulotto E, Wahl GM. Recent progress in understanding mechanisms of mammalian DNA amplification. Cell 1989;57:901-8.
14. Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL. Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci U S A 2000;97:7921-6.
15. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8.
16. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-9.
17. Crocitto LE, Korns D, Kretzner L, Shevchuk T, Blair SL, Wilson TG, et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 2004;64:821-5.
18. Munson K, Clark J, Lamparska-Kupsik K, Smith SS. Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR. Nucleic Acids Res 2007;35:2893-903.
19. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8.